Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00895011 · ClinicalTrials.gov registry record · Phase 3
Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy
A Phase 3 study, sponsored by VIVUS.
- Completed
- Registry status
- Phase 3
- Development phase
- 298
- Enrollment target
NCT00895011 is a Phase 3 study that has completed, run by VIVUS. The registered enrollment target is 298 participants.
The verdict
NCT00895011, a Phase 3 study, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 298 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety and efficacy of two doses of avanafil in the treatment of adult males for erectile dysfunction following bilateral nerve-sparing radical prostatectomy.
Interventions
- DRUG Placebo
- DRUG Avanafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00895011
The ClinicalTrials.gov registry entry for NCT00895011 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00895011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00895011 about?
NCT00895011 is a clinical study titled "Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy". The objectives of this study are to evaluate the safety and efficacy of two doses of avanafil in the treatment of adult males for erectile dysfunction following bilateral nerve-sparing radical prostatectomy.
What is the current status of trial NCT00895011?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 298 participants. The study started on 2009-04. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00895011?
The interventions under investigation include: Placebo (DRUG), Avanafil (DRUG).
Who is sponsoring clinical trial NCT00895011?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.